Patrik Jeanmonod - Feb 24, 2023 Form 4 Insider Report for Cytek Biosciences, Inc. (CTKB)

Role: Chief Financial Officer
Signature: /s/ Valerie Barnett, Attorney-in-Fact for Patrik Jeanmonod
Stock symbol: CTKB
Transactions as of: Feb 24, 2023
Transactions value $: -$33,150
Form type: 4
Date filed: 2/28/2023, 05:48 PM
Previous filing: Feb 23, 2023
Next filing: Mar 7, 2023

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	CTKB	Common Stock	Sale	-$33.2K	-3K	-2.56%	$11.05	114K	Feb 24, 2023	Direct	F1, F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 31, 2022, as last modified on September 13, 2022.
F2	The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.80 to $11.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.

Content

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 31, 2022, as last modified on September 13, 2022.

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.80 to $11.19, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.